Yihui Pan
Overview
Explore the profile of Yihui Pan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pan Y, Liu S, Shu G, Chen M, Fu L, Chen C, et al.
Cell Death Dis
. 2025 Feb;
16(1):125.
PMID: 39988631
Axitinib resistance remains a serious challenge in the treatment of advanced renal cell carcinoma (RCC), and the underlying mechanisms are not fully understood. Here, we constructed an in vivo axitinib-resistant...
2.
Li Z, Pan Y, Ma X, Lin Y, Wang X, Li H
Front Plant Sci
. 2025 Feb;
16:1473153.
PMID: 39963535
Sowing uniformity is an important evaluation indicator of mechanical sowing quality. In order to achieve accurate evaluation of sowing uniformity in hybrid rice mechanical sowing, this study takes the seeds...
3.
PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma
Shu G, Chen M, Liao W, Fu L, Lin M, Gui C, et al.
Cancer Res
. 2024 Feb;
84(10):1659-1679.
PMID: 38382068
Significance: PABPC1L functions as a key factor in renal cell carcinoma immune evasion, enhancing IDO1 and impeding T-cell function, and represents a potential target to enhance the efficacy of immune...
4.
Selective activator of human ClpP triggers cell cycle arrest to inhibit lung squamous cell carcinoma
Zhou L, Zhang T, Xue Y, Yue C, Pan Y, Wang P, et al.
Nat Commun
. 2023 Nov;
14(1):7069.
PMID: 37923710
Chemo-activation of mitochondrial ClpP exhibits promising anticancer properties. However, we are currently unaware of any studies using selective and potent ClpP activators in lung squamous cell carcinoma. In this work,...
5.
Zhu H, Song X, Pan Y, Li M, Chen L, Xiao P, et al.
Eur J Med Chem
. 2023 Jun;
258:115595.
PMID: 37385078
Glioblastoma (GBM) is an aggressive brain tumor with extremely limited clinical treatment options. Because of the blood-brain barrier (BBB), it is difficult for anti-GBM drug candidates to enter the brain...
6.
Luo L, Wei D, Pan Y, Wang Q, Feng J, Yu B, et al.
Cancer Commun (Lond)
. 2023 Jun;
43(7):808-833.
PMID: 37378422
Background: Clear cell renal cell carcinoma (ccRCC) is the most lethal renal cancer. An overwhelming increase of patients experience tumor progression and unfavorable prognosis. However, the molecular events underlying ccRCC...
7.
Zhang R, Wang P, Wei B, Chen L, Song X, Pan Y, et al.
Eur J Med Chem
. 2023 Jun;
258:115577.
PMID: 37352796
Human caseinolytic protease P (ClpP) is required for the regulatory hydrolysis of mitochondrial proteins. Allosteric ClpP agonists dysfunctionally activate mitochondrial ClpP in antileukemic therapies. We previously developed ZG111, a potent...
8.
Shu G, Lu X, Pan Y, Cen J, Huang K, Zhou M, et al.
Oncogene
. 2023 Apr;
42(22):1802-1820.
PMID: 37046045
Metastasis is the main cause of mortality in renal cell carcinoma (RCC). Circular RNAs (circRNAs) involvement in RCC metastasis has been described, although the underlying mechanisms remain unknown. We evaluated...
9.
Pan Y, Shu G, Fu L, Huang K, Zhou X, Gui C, et al.
Adv Sci (Weinh)
. 2023 Feb;
10(11):e2206792.
PMID: 36775874
High lymphocyte infiltration and immunosuppression characterize the tumor microenvironment (TME) in renal cell carcinoma (RCC). There is an urgent need to elucidate how tumor cells escape the immune attack and...
10.
Liang Y, Cen J, Huang Y, Fang Y, Wang Y, Shu G, et al.
Mol Cancer
. 2023 Jan;
22(1):14.
PMID: 36670419
No abstract available.